Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | SGK1 | O00141 | 12/20 | 0.44 |
| ▸ | SCN1A | P35498 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | SGK3 | Q96BR1 | 1/20 | 0.40 |
| ▸ | SGK2 | Q9HBY8 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5029428 | 0.92 | PIK3CA (0.45) | KDM4EGLARAB9AATMSGK1 | |
| SCHEMBL5033851 | 0.88 | SGK1 (0.48) | KDM4EGLARAB9AATMSGK1 | |
| SCHEMBL8227014 | 0.85 | PIK3CA (0.39) | KDM4EGLARAB9AATMSGK1 | |
| SCHEMBL5029432 | 0.85 | SGK1 (0.45) | KDM4EGLARAB9AATMSGK1 | |
| SCHEMBL14377331 | 0.83 | SGK1 (0.36) | SGK1CYP3A4GPR119 | |
| SCHEMBL5032067 | 0.80 | GPR119 (0.46) | MAPTCYP3A4GPR119 | |
| SCHEMBL5033801 | 0.80 | KDM4E (0.56) | KDM4EGLARAB9AATMSGK1 | |
| SCHEMBL5097294 | 0.80 | RORC (0.46) | PIK3C3KIT | |
| SCHEMBL4513513 | 0.73 | SCN9A (0.55) | KDM4EGLARAB9AATMSGK1 | |
| SCHEMBL8233270 | 0.73 | PIK3CD (0.45) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741960-B2 | Substituted aromatic compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-06-03 | — | — | US | claimed |
| EP-1983971-A2 | SUBSTITUTED AROMATIC COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2008-10-29 | — | — | EP | claimed |
| US-20070249050-A1 | Substituted aromatic compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-10-25 | — | — | US | claimed |
| WO-2007087441-A2 | SUBSTITUTED AROMATIC COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-02 | — | — | WO | claimed |
| US-20140242120-A1 | SUBSTITUTED AROMATIC COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140242120-A1 | SUBSTITUTED AROMATIC COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140242120-A1 | SUBSTITUTED AROMATIC COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-08-28 | — | — | US | disclosed |
| US-8741960-B2 | Substituted aromatic compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741960-B2 | Substituted aromatic compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741960-B2 | Substituted aromatic compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-1983971-A2 | SUBSTITUTED AROMATIC COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20070249050-A1 | Substituted aromatic compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070249050-A1 | Substituted aromatic compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070249050-A1 | Substituted aromatic compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-10-25 | — | — | US | disclosed |
| WO-2007087441-A2 | SUBSTITUTED AROMATIC COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249050-A1 | Substituted aromatic compounds for inflammation and immune-related uses | CCR1, NLRP1, NLRP3 | KDM4E 1317/4885GLA 464/4885RAB9A 1795/4885 |
| US-20140242120-A1 | SUBSTITUTED AROMATIC COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR1, NLRP1, NLRP3 | KDM4E 1317/4885GLA 464/4885RAB9A 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.